TITLE

Intrathecal Baclofen for the Treatment of Tetanus

AUTHOR(S)
Santos, M. Lurdes; Mota-Miranda, António; Alves-Pereira, António; Gomes, Armanda; Correia, José; Marçal, Nelson
PUB. DATE
February 2004
SOURCE
Clinical Infectious Diseases;2/1/2004, Vol. 38 Issue 3, p321
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Tetanus remains a serious problem in public health, particularly in developing countries, despite efficient prevention programs. A retrospective study was conducted at an infectious diseases intensive care unit during 1998–2003 involving patients admitted with grade III tetanus. The aim of the study was to evaluate the efficacy and safety of intrathecal baclofen for the treatment of tetanus. Lumbar puncture was performed, and a subarachnoid catheter was inserted for drug administration. An intrathecal bolus of baclofen was followed by a continuous infusion of 20 μg/h, until a maximum daily dose of 2 mg was provided. Twenty-two patients were treated overall. Control of the symptoms was achieved in all patients but one. Seven patients had colonization of the catheter, and 1 patient developed meningitis. All patients except one recovered. In our study, this means of treatment was efficacious and well tolerated.
ACCESSION #
12080448

 

Related Articles

  • Randomised controlled trial of tetanus treatment with antitetanus immunoglobulin by the intrathecal or intramuscular route. De Barros Miranda-Filho, Demócrito; De Alencar Ximenes, Ricardo Arraes; Barone, Antônio Alci; Vaz, Vicente Luiz; Vieira, Aderbal Gomes; Gonçalves Albuquerque, Valéria Maria // BMJ: British Medical Journal (International Edition);3/13/2004, Vol. 328 Issue 7440, p615 

    Abstract Objective To evaluate the effect of intrathecal therapy with human antitetanus immunoglobulin on clinical progression of and mortality from tetanus. Design Randomised controlled trial. Setting Intensive care unit of a university hospital, Pernambuco, Brazil. Participants 120 patients...

  • Physician-determined patient risk of toxic effects: Impact on enrollment and decision making in... Mick, Rosemarie; Lane, Neil // JNCI: Journal of the National Cancer Institute;11/16/94, Vol. 86 Issue 22, p1685 

    Characterizes physician attitudes and clinical practices regarding assessment of risk of toxic effects in patients. Existence of unexplained variability in toxicity in phase I trials; Informal scoring of patients for toxicity; Ranking of usefulness of patient factors in predicting risks of...

  • In This Issue.  // Clinical Pharmacology & Therapeutics;May2015, Vol. 97 Issue 5, p429 

    An introduction is presented where editor of the periodical discusses several topics within the issue including clinical trials on application of new therapeutics in oncology, drug dose improvement in older adults and genetic factors which affect lowering of serum uric acid related to allopurinol.

  • Drug Treatment of Functional Dyspepsia: A Systematic Analysis of Trial Methodology with Recommendations for Design of Future Trials. Van Zanten, Sander J. O. Veldhuyzen; Cleary, Cynthia; Talley, Nicolas J.; Peterson, Theresa C.; Nyrén, Olaf; Bradley, Lawrence A.; Verlinden, Marleen; Tytgat, Guido N. J. // American Journal of Gastroenterology;Apr1996, Vol. 91 Issue 4, p660 

    Objectives: To evaluate drug treatment of functional dyspepsia (including Helicobacter pylori) and provide guidelines for future trials based on a critical systematic overview of published studies. Methods: Data sources were a Medline search for articles published in English going back...

  • Phase III trial of oral MS treatment begins.  // Inside MS;Aug/Sep2005, Vol. 23 Issue 4, p29 

    Reports on the initiation of the trial of Mylinax, an oral form of multiple sclerosis (MS) therapy, in people with relapsing forms of MS. Information on Mylinax; Commencement of the enrollment for the trial in Canada; Background on clinical trials.

  • Phase I Clinical Trials Update: June 2013.  // BioWorld Insight;7/15/2013, Vol. 21 Issue 29, p7 

    A table providing updates on phase one clinical trials of several drugs and their company including the AFM13 from Affimed Therapeutics AG, the BGB324 from Bergenbio AS and the MPDL3280A from Genentech Inc. is presented and also presents information on their clinical use and mode of action.

  • Viral testing key to reducing inappropriate antibiotic use.  // Infectious Disease News;Dec2012, Vol. 25 Issue 12, p39 

    The article discusses a study on the effectiveness of viral testing in reducing unnecessary antibiotic prescriptions for children.

  • Quantifying biased agonism: understanding the links between affinity and efficacy. Rajagopal, Sudarshan // Nature Reviews Drug Discovery;Jun2013, Vol. 12 Issue 6, p483 

    A letter to the editor is presented in response to the article "Signalling bias in new drug discovery: detection, quantification and therapeutic impact," by T. Kenakin and A. Christopoulos in the 2013 issue.

  • Recombinant human erythropoietin attenuates weight loss in a murine cancer cachexia model. van Halteren, H.K.; Bongaerts, G.P.A.; Verhagen, C.A.M.; Kamm, Y.J.L.; Willems, J.L.; Grutters, G.J.; Koopman, J.P.; Wagener, D.J.Th. // Journal of Cancer Research & Clinical Oncology;Apr2004, Vol. 130 Issue 4, p211 

    Background: Within hypoxic tumor regions anaerobic dissimilation of glucose is the sole source of energy generation. It yields only 5% of the ATP that is normally gained by means of oxidative glucose catabolism. The increased need for glucose may aggravate cancer cachexia. We investigated the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics